Shared on20 Aug 25Fair value Increased 101%
The notable increase in Oncopeptides' fair value target is primarily driven by a higher forecasted future P/E multiple, despite a marginal dip in revenue growth expectations, with the analyst consensus price target rising from SEK2.73 to SEK3.25. What's in the News Strategic partnership with SD Pharma enhances Pepaxti's hospital reach in Spain without upfront costs, starting Q3 2025.
Shared on30 Jul 25Fair value Decreased 8.58%
Despite a substantial improvement in net profit margin and a lower future P/E ratio, reflecting enhanced profitability and potentially more attractive valuation, the consensus Analyst Price Target for Oncopeptides has been revised downward from SEK2.99 to SEK2.73. What's in the News Two real-world evidence posters on Pepaxti for relapsed/refractory multiple myeloma accepted for presentation at the International Myeloma Society Annual Meeting, highlighting growing clinical use and importance of real-world data.
Shared on01 May 25Fair value Decreased 4.78%
AnalystConsensusTarget has increased profit margin from 16.6% to 18.7% and decreased future PE multiple from 14.2x to 12.0x.
Shared on24 Apr 25Fair value Increased 15%
AnalystConsensusTarget has decreased profit margin from 19.8% to 16.6%, increased future PE multiple from 9.5x to 14.2x and increased shares outstanding growth rate from 0.0% to 0.1%.